• Explore /
  • Poster
  • / A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer.

A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer.

Abstract Poster

Authors

null

Xavier B. Pivot

University Hospital Jean Minjoz, Besançon, France

Xavier B. Pivot , Igor Bondarenko , Mikhail Dvorkin , Ekaterina Trishkina , Jin-Hee Ahn , Seock-Ah Im , Tomasz Sarosiek , Sanjay Chattopadhyay , Marek Wojtukiewicz , Vladimir Moiseyenko , Yaroslav V. Shparyk , Maximino De Guzman Bello III, Vladimir Semiglazov , Sujeong Song , Jae Yun Lim

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Clinical Trial Registration Number

NCT02149524

Citation

J Clin Oncol 35, 2017 (suppl; abstr 509)

DOI

10.1200/JCO.2017.35.15_suppl.509

Abstract #

509

Poster Bd #

109

Abstract Disclosures

Similar Posters

First Author: Justin Stebbing

First Author: Christian Jackisch

First Author: Atara Isaiah Ntekim

First Author: Theodoros Foukakis